Clinical implications of insulin-like growth factor II mRNA-binding protein 3 expression in non-small cell lung carcinoma

Zhang,Jinhui; Ou,Yingfu; Ma,Yibing; Zheng,Linlin; Zhang,Xiaokang; Xia,Rongjun; Kong,Fanyong; Shen,Yue; Wang,Shiqing; Lin,Lijuan

doi:10.3892/ol.2015.2910

Clinical implications of insulin-like growth factor II mRNA-binding protein 3 expression in non-small cell lung carcinoma

Authors:
- Jinhui Zhang
- Yingfu Ou
- Yibing Ma
- Linlin Zheng
- Xiaokang Zhang
- Rongjun Xia
- Fanyong Kong
- Yue Shen
- Shiqing Wang
- Lijuan Lin
View Affiliations

Affiliations: Institute of Molecular Medicine, Medical College, Eastern Liaoning University, Dandong, Liaoning 118000, P.R. China, Department of Pathology, Dandong Centre Hospital, Dandong, Liaoning 118000, P.R. China
Published online on: January 27, 2015 https://doi.org/10.3892/ol.2015.2910
Pages: 1927-1933

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to examine the role of insulin‑like growth factor II mRNA‑binding protein 3 (IMP3) expression for the prognostic evaluation of non‑small cell lung carcinoma (NSCLC), a total of 186 breast cancer patients, with adjacent non‑tumor lung tissues, were selected for immunohistochemical staining of IMP3 protein. The NSCLC tissues and paired adjacent non‑tumor tissues of six patients were quantified using reverse transcription quantitative polymerase chain reaction. The correlations between IMP3 overexpression and the clinical features of NSCLC were evaluated using the χ2 test and Fisher's exact test. The survival rate was calculated using the Kaplan‑Meier method, and the association between prognostic factors and patient survival was also analyzed by Cox's proportional hazards models. The results showed that IMP3 protein exhibited a mainly cytoplasmic staining pattern in the NSCLC tissues. The positive rate of IMP3 protein expression was 74.7% (139/186) in the NSCLC tissues and was significantly higher than the rate of 19.9% (37/186) in the adjacent non‑tumor tissues. The expression rate of the NQO1 protein was correlated with a large tumor size, poor differentiation, lymph node metastasis, late clinical stage, and disease‑free and overall survival rates in the NSCLC patients. In the early‑ and late‑stage NSCLC groups, the disease‑free and overall survival rates of the patients with IMP3 expression were significantly lower than those of the patients without IMP3 expression. Further analysis using Cox's proportional hazard regression model revealed that IMP3 expression was a significant independent hazard factor for the overall survival rate of patients with NSCLC. In conclusion, the present study found that IMP3 plays a significant role in the progression of NSCLC, and that it may potentially be used as an independent biomarker for prognostic evaluation of the cancer.

View Figures

View References

1	Brambilla E, Travis WD, Colby TV, et al: The new World Health Organization classification of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar
2	Lokk K, Vooder T, Kolde R, et al: Methylation markers of early-stage non-small cell lung cancer. PLoS One. 7:e398132012. View Article : Google Scholar : PubMed/NCBI
3	Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, et al: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer. 10:3412010. View Article : Google Scholar : PubMed/NCBI
4	Mentrikoski MJ, Ma L, Pryor JG, et al: Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes. Mod Pathol. 22:1582–1587. 2009. View Article : Google Scholar : PubMed/NCBI
5	Hoffmann NE, Sheinin Y, Lohse CM, et al: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer. 112:1471–1479. 2008. View Article : Google Scholar : PubMed/NCBI
6	Jiang Z, Chu PG, Woda BA, et al: Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res. 14:5579–5584. 2008. View Article : Google Scholar : PubMed/NCBI
7	Schaeffer DF, Owen DR, Lim HJ, et al: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 10:592010. View Article : Google Scholar : PubMed/NCBI
8	Mhawech-Fauceglia P, Herrmann FR, Rai H, et al: IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol. 133:899–908. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lu D, Yang X, Jiang NY, et al: IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol. 35:1638–1645. 2011. View Article : Google Scholar : PubMed/NCBI
10	Hammer NA, Hansen Tv, Byskov AG, et al: Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction. 130:203–212. 2005. View Article : Google Scholar : PubMed/NCBI
11	Chen LT, Lin LJ and Zheng LL: The correlation between insulin-like growth factor II mRNA binding protein 3 expression in hepatocellular carcinoma and prognosis. Hepatogastroenterology. 60:553–556. 2013.
12	Lin L, Zhang J, Wang Y, et al: Insulin-like growth factor-II mRNA-binding protein 3 predicts a poor prognosis for colorectal adenocarcinoma. Oncol Lett. 6:740–744. 2013.PubMed/NCBI
13	Singletary SE, Greene FL and Sobin LH: Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer. 98:2740–2741. 2003. View Article : Google Scholar : PubMed/NCBI
14	Liao B, Hu Y and Brewer G: RNA-binding protein insulin-like growth factor mRNA-binding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation. J Biol Chem. 286:31145–31152. 2011. View Article : Google Scholar : PubMed/NCBI
15	Gredes T, Spassov A, Mai R, et al: Changes in insulin like growth factors, myostatin and vascular endothelial growth factor in rat musculus latissimus dorsi by poly-3-hydroxybutyrate implants. J Physiol Pharmacol. 60(Suppl 3): 77–81. 2009.
16	Ozdemir NO, Türk NS and Düzcan E: IMP3 expression in urothelial carcinomas of the urinary bladder. Turk Patoloji Derg. 27:31–37. 2011.PubMed/NCBI
17	Liao B, Hu Y, Herrick DJ and Brewer G: The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 280:18517–18524. 2005. View Article : Google Scholar : PubMed/NCBI
18	Vikesaa J, Hansen TV, Jønson L, et al: RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 25:1456–1468. 2006. View Article : Google Scholar : PubMed/NCBI
19	Yamamoto H, Arakaki K, Morimatsu K, et al: Insulin-like growth factor II messenger RNA-binding protein 3 expression in gastrointestinal mesenchymal tumors. Hum Pathol. 45:481–487. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lee DJ, Xylinas E, Rieken M, et al: Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol. 66:379–385. 2014. View Article : Google Scholar : PubMed/NCBI
21	Beljan Perak R, Durdov MG, Capkun V, et al: IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol. 7:1652012. View Article : Google Scholar : PubMed/NCBI
22	Lin L, Zhang J, Wang Y, et al: Expression of insulin-like growth factor 2 mRNA-binding protein 3 expression and analysis of prognosis in the patients with lung squamous cell carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 29:694–697. 2013.PubMed/NCBI